ATC code: S01XA20.
Pharmacology: Pharmacodynamics: The usual management of dry eye is with artificial tears.
Alleviation of symptoms and an increase in tear film stability has been shown after topical application of sodium hyaluronate solution. Sodium hyaluronate might play a role in maintaining a healthy corneal epithelium.
Pharmacokinetics: High molecular weight molecules such as sodium hyaluronate are not expected to pass through the conjunctiva and the corneal epithelium.
Toxicology: Preclinical safety data: No maternal toxicity, fetal toxicity, or teratogenic effects on the fetuses of treated dams (rats or rabbits) has been observed after subcutaneous sodium hyaluronate administration at doses up to 50 mg/kg/day. Sodium hyaluronate has shown no mutagenic or clastogenic potential in bacterial assays and cytogenetic assays conducted both in vitro and in vivo.